Related Experiment Video
Updated: Jan 12, 2026
09:10
DetectSyn: A Rapid, Unbiased Fluorescent Method to Detect Changes in Synapse Density
Published on: July 22, 2022
3.7K
EZHIP boosts neuronal-like synaptic gene programs and depresses polyamine metabolism
Elham Hasheminasabgorji1,2, Huey-Miin Chen3,4, Taylor A Gatesman5
1Cumming School of Medicine, Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, T2N 4N1, Canada.
Acta Neuropathologica Communications
|November 7, 2025
Summary
EZHIP mutations are found in various pediatric brain tumors, not just PFA. This study reveals EZHIP's role in neuronal gene programs and metabolism, expanding its known functions beyond H3K27me3 repression.
Area of Science:
- Neuro-oncology
- Epigenetics
- Cancer Genomics
Background:
- Loss of H3K27me3 in PFA ependymoma and diffuse midline glioma (DMG) is linked to EZHIP and H3K27M, respectively.
- EZHIP mutations are rare in PFA, but its broader role and functions are unknown.
Purpose of the Study:
- Investigate EZHIP's mutational landscape in pediatric brain tumors.
- Elucidate EZHIP's functional roles beyond H3K27me3 repression.
Main Methods:
- Analyzed EZHIP mutations across pediatric brain tumor types.
- Expressed EZHIP in human neural models for transcriptomic and metabolomic analysis.
Main Results:
- EZHIP mutations identified in PFA, medulloblastoma, and pediatric high-grade glioma (HGG), including H3K27M-positive DMG.
- Mutant EZHIP is expressed in H3K27M-positive DMG; HGG cases co-occur with EGFR mutations.
- EZHIP expression promotes neuronal gene programs and represses methionine/polyamine metabolism.
Conclusions:
- EZHIP mutations are present in a wider range of pediatric brain tumors than previously thought.
- EZHIP influences neuronal function and metabolism, suggesting links between metabolic and epigenetic changes in PFA.
- This study expands the understanding of EZHIP's function in pediatric cancers.
Related Concept Videos
01:29Drugs Affecting Neurotransmitter Synthesis
2.1K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.1K
01:21Drugs Affecting Neurotransmitter Release or Uptake
1.5K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.5K
01:28Human Genetics
1.4K
Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
The complex relationship between genetics and psychology is observable through common biological components such...
1.4K
01:29Excitatory and Inhibitory Effects of Neurotransmitters
12.5K
When an action potential reaches the presynaptic axon terminal, it releases neurotransmitters from the neuron into the synaptic cleft at a chemical synapse. The released neurotransmitter can be excitatory or inhibitory. The critical criteria commonly used to determine whether a molecule is a neurotransmitter at a chemical synapse are the molecule's presence in the presynaptic neuron. Second, its release is in response to strong presynaptic depolarization. And lastly, the presence of...
12.5K
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
802
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
802
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
527
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
527